# Hercules Capital

> Hercules Capital is a VC fund backing Biotechnology and Health Care. See 222 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 222
- Last investment: Aug 2026
- Lead investor: 57%
- Last fund: Jun 2010
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/hercules-technology-growth-capital
- X (Twitter): https://twitter.com/htgcinc
- Website: http://www.htgc.com

Hercules Capital is a VC fund in Palo Alto focused on Biotechnology and Health Care. Hercules is a non-bank lender to venture capital-backed companies at all stages of development in a broadly diversified variety of technology, life sciences, and sustainable and renewable technology industries.With over a decade of experience in venture debt, Hercules is uniquely positioned to create innovative financing solutions that perfectlyfit within a company's existing capital structure and map to its business objectives. Recognized as the industry leader, Hercules understands the flexibility these types of companies need and has the experience to work closely with them, even through challenging times, to help them reach critical milestones.Hercules' deep sector expertise, geographic presence, and strong capital base have made Hercules the lender of choice for more than 480 innovative companies.

## Contacts

5 contacts available for Hercules Capital. Shizune tracks 16 team members at Hercules Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/herculescapital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 84 | 38% |
| Health Care | 69 | 31% |
| Pharmaceutical | 34 | 15% |
| Medical | 33 | 15% |
| Software | 29 | 13% |

164 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Debt | 72 | 32% |
| Debt Financing | 60 | 27% |
| Funding Round | 14 | 6% |
| Series E | 9 | 4% |
| Series D | 6 | 3% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 140 | 63% |
| United Kingdom | 9 | 4% |
| Germany | 3 | 1% |
| Switzerland | 3 | 1% |
| Spain | 2 | 1% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cristy Barnes | Managing Director | 9 | — |
| Janice Bourque | Managing Director, Life Sciences | 2 | — |
| John Eggbeer | Managing Director | 2 | — |
| Joseph Hoffman | Director | 0 | — |
| Lake McGuire | Managing Director \| Life Sciences | 3 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Valar Atomics | Uses nuclear fission to create gas and oil from ambient air. | $200M | Debt Financing | Aug 03, 2026 |  |
| 4D Molecular Therapeutics | 4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions. | $200M | Post-IPO Debt | Jun 29, 2026 |  |
| Dyne Therapeutics | Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives. | $200M | Post-IPO Debt | Jun 17, 2026 |  |
| Beren Therapeutics | Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Thousand Oaks, CA. | $165M | Debt Financing | Jun 10, 2026 |  |
| Perk (formerly TravelPerk) | TravelPerk is a next-generation business travel booking and management platform for companies of any size. It is an all-in-one platform for booking business travel. TravelPerk is backed by investors such as Spark Capital, investors in Slack, Trello, and Twitter. The company is co-founded and funded by a team of entrepreneurial executives with deepmarket expertise, including leadership-level experience, as one of the successful players in the online travel industry. One of the co-founders recently started and sold a travel technology company to one of the players in the market.TravelPerk was founded in 2015 and is headquartered in Barcelona, Catalonia. | $300M | Debt Financing | Jun 03, 2026 |  |
| Perk.com | Perk is the #1 Mobile Rewards program with millions of members worldwide. Perk believes that advertising today is a one-way street and pits advertisers against users and publishers. Perk is aiming to make the world more rewarding by creating a better relationship between advertisers, consumers, and publishers. | $300M | Debt Financing | Jun 03, 2026 |  |
| Lexicon Pharmaceuticals | Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trialsfor the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology. | $55M | Post-IPO Debt | May 04, 2026 |  |
| Hermeus | Hermeus is an aerospace and defense company that develops hypersonic aircraft capable of reaching speeds around Mach 5. The company’s core mission is to drastically reduce global travel times by creating next-generation aircraft that can fly significantly faster than traditional commercial jets. Its flagship programs include the Quarterhorse seriesof high-speed test aircraft and the development of the Chimera engine, a turbine-based combined cycle propulsion system designed for hypersonic flight. Hermeus follows a rapid, iterative development approach, building and testing multiple prototypes to accelerate innovation and reduce engineering timelines. The company collaborates with organizations such as the U.S. Air Force and NASA, positioning its technology for both commercial aviation and defense applications. | $150M | Debt Financing | Apr 07, 2026 |  |
| Intercom | Intercom is a Conversational Relationship Platform (CRP) that helps businesses build better customer relationships through personalized, messenger-based experiences. It’s the only platform that delivers conversational experiences across the customer journey, with solutions for Conversational Marketing, Conversational Customer Engagement andConversational Support.Intercom is bringing a messenger-first experience to all business-to-customer communication, powering 500 million conversations per month and connecting 4 billion unique end users worldwide across its more than 25,000 paying customers, including Atlassian, Sotheby’s and New Relic.The company was founded in 2011 in San Francisco by Eoghan McCabe, Des Traynor, Ciaran Lee and David Barrett, with the mission to make internet business personal. Intercom was valued at $1.275 billion in 2018 and has secured $241 million in funding from investors including Kleiner Perkins, Bessemer Venture Partners and Social Capital. | $250M | Debt Financing | Mar 09, 2026 |  |
| Fin | Fin is the Customer Agent company delivering perfect customer experiences – from support to sales to commerce. 30,000+ companies use our products. Fin resolves over 2 million conversations weekly, is doubling growth year on year, and has surpassed $400M in annual recurring revenue. Founded as Intercom in 2011, we revolutionized modern customercommunication. When it became clear AI would fundamentally reshape the industry, we reinvented the company – rebuilding our product, infrastructure, and team around AI. Still founder-led, we're one of the largest and fastest-growing private software companies in the world, with more than 1,400 people across six global offices. | $250M | Debt Financing | Mar 09, 2026 |  |

10 of 222 investments shown.

## Co-investors
- [Silicon Valley Bank](https://shizune.co/investors/profile/silicon-valley-bank) — VC Fund, 13 deals together
- [InterWest Partners](https://shizune.co/investors/profile/interwest-partners) — VC Fund, 5 deals together
- [JP Morgan](https://shizune.co/investors/profile/jp-morgan-chase) — VC Fund, 5 deals together
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund, 3 deals together
- [Armentum Partners](https://shizune.co/investors/profile/armentum-partners) — VC Fund, 3 deals together
- [DN Capital](https://shizune.co/investors/profile/dn-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does Hercules Capital invest in?

Hercules Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Debt and Debt Financing stage. Most of the 222 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Hercules Capital?

Public channels for Hercules Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Hercules Capital?

The team at Hercules Capital includes Cristy Barnes (Managing Director), Janice Bourque (Managing Director, Life Sciences) and John Eggbeer (Managing Director), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co